Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia

被引:16
作者
Chang, Vivian Y. [1 ]
Basso, Giuseppe [2 ]
Sakamoto, Kathleen M. [3 ]
Nelson, Stanley F. [4 ]
机构
[1] Univ Calif Los Angeles, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Padua, Woman & Child Hlth Dept, I-335128 Padua, Italy
[3] Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA
[4] Univ Calif Los Angeles, Dept Human Genet Pathol & Lab Med, Los Angeles, CA 90095 USA
来源
BMC CANCER | 2013年 / 13卷
关键词
Pediatric leukemia; Congenital acute lymphoblastic leukemia; Exome sequencing; ACUTE MYELOID-LEUKEMIA; MLL REARRANGEMENTS; KINASE INHIBITOR; DISCOVERY; FRAMEWORK; INFANT;
D O I
10.1186/1471-2407-13-55
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute lymphoblastic leukemia (ALL) diagnosed within the first month of life is classified as congenital ALL and has a significantly worse outcome than ALL diagnosed in older children. This suggests that congenital ALL is a biologically different disease, and thus may be caused by a distinct set of mutations. To understand the somatic and germline mutations contributing to congenital ALL, the protein-coding regions in the genome were captured and whole-exome sequencing was employed for the identification of single-nucleotide variants and small insertion and deletions in the germlines as well as the primary tumors of four patients with congenital ALL. Methods: Exome sequencing was performed on Illumina GAIIx or HiSeq 2000 (Illumina, San Diego, California). Reads were aligned to the human reference genome and the Genome Analysis Toolkit was used for variant calling. An in-house developed Ensembl-based variant annotator was used to richly annotate each variant. Results: There were 1-3 somatic, protein-damaging mutations per ALL, including a novel mutation in Sonic Hedgehog. Additionally, there were many germline mutations in genes known to be associated with cancer predisposition, as well as genes involved in DNA repair. Conclusion: This study is the first to comprehensively characterize the germline and somatic mutational profile of all protein-coding genes patients with congenital ALL. These findings identify potentially important therapeutic targets, as well as insight into possible cancer predisposition genes.
引用
收藏
页数:6
相关论文
共 25 条
  • [11] Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia
    Montes, Rosa
    Ayllon, Veronica
    Gutierrez-Aranda, Ivan
    Prat, Isidro
    Carmen Hernandez-Lamas, M.
    Ponce, Laura
    Bresolin, Silvia
    Te Kronnie, Geertruy
    Greaves, Mel
    Bueno, Clara
    Menendez, Pablo
    [J]. BLOOD, 2011, 117 (18) : 4746 - 4758
  • [12] Prognostic factors in infants with acute myeloid leukemia
    Pui, CH
    Raimondi, SC
    Srivastava, DK
    Tong, X
    Behm, FG
    Razzouk, B
    Rubnitz, JE
    Sandlund, JT
    Evans, WE
    Ribeiro, R
    [J]. LEUKEMIA, 2000, 14 (04) : 684 - 687
  • [13] PUI CH, 1991, BLOOD, V77, P440
  • [14] Integrative genomics viewer
    Robinson, James T.
    Thorvaldsdottir, Helga
    Winckler, Wendy
    Guttman, Mitchell
    Lander, Eric S.
    Getz, Gad
    Mesirov, Jill P.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (01) : 24 - 26
  • [15] RUBNITZ JE, 1994, BLOOD, V84, P570
  • [16] Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma
    Saarinen, Silva
    Aavikko, Mervi
    Aittomaki, Kristiina
    Launonen, Virpi
    Lehtonen, Rainer
    Franssila, Kaarle
    Lehtonen, Heli J.
    Kaasinen, Eevi
    Broderick, Peter
    Tarkkanen, Jussi
    Bain, Barbara J.
    Bauduer, Frederic
    Unal, Ali
    Swerdlow, Anthony J.
    Cooke, Rosie
    Makinen, Markus J.
    Houlston, Richard
    Vahteristo, Pia
    Aaltonen, Lauri A.
    [J]. BLOOD, 2011, 118 (03) : 493 - 498
  • [17] Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants
    Satake, N
    Maseki, N
    Nishiyama, M
    Kobayashi, H
    Sakurai, M
    Inaba, H
    Katano, N
    Horikoshi, Y
    Eguchi, H
    Miyake, M
    Seto, M
    Kaneko, Y
    [J]. LEUKEMIA, 1999, 13 (07) : 1013 - 1017
  • [18] Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    Smith, BD
    Levis, M
    Beran, M
    Giles, F
    Kantarjian, H
    Berg, K
    Murphy, KM
    Dauses, T
    Allebach, J
    Small, D
    [J]. BLOOD, 2004, 103 (10) : 3669 - 3676
  • [19] Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
    Stone, R. M.
    Fischer, T.
    Paquette, R.
    Schiller, G.
    Schiffer, C. A.
    Ehninger, G.
    Cortes, J.
    Kantarjian, H. M.
    DeAngelo, D. J.
    Huntsman-Labed, A.
    Dutreix, C.
    del Corral, A.
    Giles, F.
    [J]. LEUKEMIA, 2012, 26 (09) : 2061 - 2068
  • [20] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    Stone, RM
    DeAngelo, DJ
    Klimek, V
    Galinsky, I
    Estey, E
    Nimer, SD
    Grandin, W
    Lebwohl, D
    Wang, YF
    Cohen, P
    Fox, EA
    Neuberg, D
    Clark, J
    Gilliland, DG
    Griffin, JD
    [J]. BLOOD, 2005, 105 (01) : 54 - 60